Skip to main content
    V

    Vir Biotechnology Inc (VIR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $9.58
    -0.38 (-3.82%)

    Market Cap: $1.71B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Vir Biotechnology Inc (VIR) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Vir Biotechnology (VIR) trades at 5.4x sales and 1.8x book value. Its P/S of 5.4x is below its 5-year median of 12.5x. Its forward P/E is 4.3x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/E4.3x
    Price to sales5.4x
    Price to book1.8x
    PEGN/A
    FCF yield-8.7%
    As of Nov 17, 2026

    Historical Medians

    MultipleCurrent5-year median10-year median
    P/S5.4x12.5xN/A
    P/B1.8x1.2xN/A
    Medians of month-end values through Oct 2026: 60 months (5-year).

    Valuation History

    Over the 7 year ends shown, its P/S ranged from 2.1x in 2022 to 62.6x in 2019.

    Year endPriceP/EP/SP/B
    2025$6.03N/A12.2x1.1x
    2024$7.34N/A13.4x0.9x
    2023$10.06N/A15.6x0.9x
    2022$25.316.6x2.1x1.6x
    2021$41.8710.8x5.1x3.9x
    2020$26.78N/A40.3x4.8x
    2019$12.58N/A62.6x2.7x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About VIR

    What is VIR's forward P/E ratio?

    Vir Biotechnology has a forward P/E ratio of 4.3x.

    Is VIR stock overvalued?

    GNG's valuation label for VIR is Fairly valued.

    What is VIR's price to sales ratio?

    Vir Biotechnology has a price to sales ratio of 5.4x.